Breaking News Instant updates and real-time market news.

HSIC

Henry Schein

$72.18

0.43 (0.60%)

06:46
02/13/18
02/13
06:46
02/13/18
06:46

Henry Schein denies FTC anti-trust allegations

Henry Schein issued the following statement in response to allegations made about the Company by the U.S. Federal Trade Commission in a press release dated Feb.12, 2018: "Based on the FTC's press release, the Company is being accused of participating in a conspiracy to refuse to provide discounts to, or compete for, the business of buying groups. Contrary to the FTC's allegations, the Company was a leader in supplying buying groups, has consistently done business with buying groups, has a dedicated team to serve buying groups, and never entered into an agreement with others to refuse to do business with buying groups. Based on the FTC's original definition of buying groups, the Company does business with more than 100 buying groups. Even under a narrower definition recently advanced by the FTC, the Company has done business, and continues to do business, with the very groups it is now accused of boycotting. The Company believes that the allegations as described in the press release are meritless and intends to defend itself vigorously. The Company does not anticipate that this matter will have a material adverse effect on our financial condition or results of operations."

  • 16

    Feb

HSIC Henry Schein
$72.18

0.43 (0.60%)

12/08/17
DBAB
12/08/17
INITIATION
Target $79
DBAB
Buy
Henry Schein initiated with a Buy at Deutsche Bank
Deutsche Bank analyst Glen Santangelo started Henry Schein (HSIC) with a Buy rating and $79 price target. The stock over the last five months is down 27% as investors have become increasingly concerned about the potential increased presence of Amazon (AMZN) in the sector and overall declining growth, Santangelo tells investors in a research note. He believes near-term fears are reflected in the shares and recommends buying the pullback.
12/19/17
DBAB
12/19/17
NO CHANGE
Target $79
DBAB
Buy
Deutsche Bank survey finds dentists mixed on Amazon
Deutsche Bank analyst Glen Santangelo says his firm's survey of 81 dentists "somewhat supports" the view that dentists are not overly convinced that purchasing consumables online is the obvious choice for their practice. The analyst does not believe the "near-term reality matches the current level of fear" regarding competition from Amazon (AMZN). The threat of Amazon and the potential for increased online competition has weighed on sentiment of Henry Schein (HSIC) over the last few months, Santangelo tells investors in a research note. He points out the stock is down 7% for the year after declining 4% in 2016. Santangelo believes Henry Schein has the potential to see a rebound in both consumable and equipment growth, creating an attractive risk/reward for the stock heading into 2018. The analyst keeps a Buy rating on the shares with a $79 price target. Other names in the dental supply space include Patterson Companies (PDCO) and Dentsply Sirona (XRAY).
12/27/17
PIPR
12/27/17
NO CHANGE
Target $78
PIPR
Overweight
Piper sees Henry Schein positioned well against Amazon in Florida
After visiting one of Henry Schein's (HSIC) top five consumable distribution centers, in Jacksonville, Florida, a market where Amazon (AMZN) has recently made investments, Piper Jaffray analyst Sarah James says the company's offerings may stack up well to Amazon. She highlights Henry Schein's ability to distribute 94% of orders next day with a 99% accuracy rate. The analyst believes the company's customer retention could be higher than the market expects driven by partnerships with dentists to manage inventory and maximize revenue generating space. Henry Schein's main defense against Amazon is customer service and the "sticky behavior" of doctors/dentists, James tells investors in a research note titled "Learning from Ground Zero of the War on Amazon and Dental Consumable Trends." She keeps an Overweight rating on Henry Schein with a $78 price target.
01/04/18
EVER
01/04/18
INITIATION
Target $81
EVER
Outperform
Henry Schein initiated with an Outperform at Evercore ISI
Evercore ISI started Henry Schein with an Outperform rating and $81 price target.

TODAY'S FREE FLY STORIES

FSLR

First Solar

$66.28

-0.42 (-0.63%)

05:44
02/23/18
02/23
05:44
02/23/18
05:44
Recommendations
First Solar analyst commentary  »

First Solar outlook has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Mar

HPP

Hudson Pacific

$30.66

0.42 (1.39%)

05:41
02/23/18
02/23
05:41
02/23/18
05:41
Upgrade
Hudson Pacific rating change  »

Hudson Pacific upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OJSCY

Rosneft

05:40
02/23/18
02/23
05:40
02/23/18
05:40
Downgrade
Rosneft rating change  »

Rosneft downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MIC

Macquarie Infrastructure

$37.41

-26.21 (-41.20%)

05:39
02/23/18
02/23
05:39
02/23/18
05:39
Downgrade
Macquarie Infrastructure rating change  »

Macquarie Infrastructure…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACIA

Acacia Communications

$41.84

-1.6 (-3.68%)

05:39
02/23/18
02/23
05:39
02/23/18
05:39
Downgrade
Acacia Communications rating change  »

Acacia Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 13

    Mar

  • 29

    Mar

XPO

XPO Logistics

$93.56

-0.43 (-0.46%)

05:37
02/23/18
02/23
05:37
02/23/18
05:37
Recommendations
XPO Logistics analyst commentary  »

XPO free cash flow growth…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$39.85

0.34 (0.86%)

, BIVV

Bioverativ

$104.30

0.39 (0.38%)

05:35
02/23/18
02/23
05:35
02/23/18
05:35
Hot Stocks
Sanofi announces expiration of HSR waiting period for acquisition of Bioverativ »

Sanofi (SNY) announced…

SNY

Sanofi

$39.85

0.34 (0.86%)

BIVV

Bioverativ

$104.30

0.39 (0.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Mar

  • 25

    Mar

  • 25

    Apr

  • 02

    May

KNX

Knight-Swift

$47.83

-0.47 (-0.97%)

05:34
02/23/18
02/23
05:34
02/23/18
05:34
Recommendations
Knight-Swift analyst commentary  »

Knight-Swift consensus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBGL

Sibanye Gold

$4.05

-0.38 (-8.58%)

05:26
02/23/18
02/23
05:26
02/23/18
05:26
Upgrade
Sibanye Gold rating change  »

Sibanye Gold upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INGIF

Ingenico Group

05:23
02/23/18
02/23
05:23
02/23/18
05:23
Downgrade
Ingenico Group rating change  »

Ingenico Group downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOMO

Momo

$30.53

-1.44 (-4.50%)

05:22
02/23/18
02/23
05:22
02/23/18
05:22
Hot Stocks
Momo acquires Tantan in cash, stock transaction »

Momo announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDDY

GoDaddy

$55.43

-0.27 (-0.48%)

05:20
02/23/18
02/23
05:20
02/23/18
05:20
Recommendations
GoDaddy analyst commentary  »

GoDaddy price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 28

    Mar

SRE

Sempra Energy

$106.64

1.21 (1.15%)

05:19
02/23/18
02/23
05:19
02/23/18
05:19
Hot Stocks
Sempra Energy raises annualized dividend by 9% to $3.58 per share »

Sempra Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

MB

Mindbody

$35.55

2.2 (6.60%)

05:18
02/23/18
02/23
05:18
02/23/18
05:18
Recommendations
Mindbody analyst commentary  »

Mindbody price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 26

    Feb

  • 26

    Feb

FNGN

Financial Engines

$29.95

-0.45 (-1.48%)

05:17
02/23/18
02/23
05:17
02/23/18
05:17
Upgrade
Financial Engines rating change  »

Financial Engines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OKTA

Okta

$35.82

0.49 (1.39%)

05:14
02/23/18
02/23
05:14
02/23/18
05:14
Initiation
Okta initiated  »

Okta initiated with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 26

    Feb

  • 07

    Mar

COTV

Cotiviti Holdings

$34.21

-0.32 (-0.93%)

05:11
02/23/18
02/23
05:11
02/23/18
05:11
Downgrade
Cotiviti Holdings rating change  »

Cotiviti downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARD

Ardagh Group

$19.01

0.8 (4.39%)

05:09
02/23/18
02/23
05:09
02/23/18
05:09
Recommendations
Ardagh Group analyst commentary  »

Ardagh should be bought…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSX

Boston Scientific

$26.48

-0.29 (-1.08%)

05:03
02/23/18
02/23
05:03
02/23/18
05:03
Initiation
Boston Scientific initiated  »

Boston Scientific assumed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

  • 01

    Mar

  • 14

    Mar

SGMO

Sangamo

$25.40

3.2 (14.41%)

, GILD

Gilead

$79.40

-1.29 (-1.60%)

05:00
02/23/18
02/23
05:00
02/23/18
05:00
Recommendations
Sangamo, Gilead analyst commentary  »

Sangamo price target…

SGMO

Sangamo

$25.40

3.2 (14.41%)

GILD

Gilead

$79.40

-1.29 (-1.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EMN

Eastman Chemical

$101.51

0.42 (0.42%)

04:55
02/23/18
02/23
04:55
02/23/18
04:55
Conference/Events
Eastman Chemical management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

04:55
02/23/18
02/23
04:55
02/23/18
04:55
General news
Breaking General news story  »

Week of 2/23 Baker-Hughes…

04:55
02/23/18
02/23
04:55
02/23/18
04:55
General news
Breaking General news story  »

San Francisco Federal…

UMICY

Umicore

$14.37

-0.185 (-1.27%)

04:55
02/23/18
02/23
04:55
02/23/18
04:55
Conference/Events
Umicore management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

GVA

Granite Construction

$60.58

1.04 (1.75%)

04:55
02/23/18
02/23
04:55
02/23/18
04:55
Conference/Events
Granite Construction management to meet with MKM Partners »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 23

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.